Obicetrapib for Cholesterol Levels
AB
Overseen byArchna Bajaj, MD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Waitlist Available
Sponsor: NewAmsterdam Pharma
Trial Summary
What is the purpose of this trial?
To determine the treatment effect with obicetrapib (10 mg) on the fractional catabolic rate (FCR) of apolipoprotein (apo) B100 in low-density lipoprotein (LDL).
Research Team
AB
Archna Bajaj, MD
Principal Investigator
University of Pennsylvania
Eligibility Criteria
This trial is for men and women aged 18-75 who are in good health as determined by a doctor, have had a stable weight for at least 6 weeks, and have a BMI between >18.5 and ≤40 kg/m2. Women must not be pregnant or breastfeeding. Participants should have normal triglyceride levels and been on certain statin medications for at least 4 weeks.Inclusion Criteria
My fasting triglyceride level is ≤ 400 mg/dL and I've been on specific cholesterol medications for at least 4 weeks.
The study leader considers me healthy based on my recent health checks and tests.
I am between 18 and 75 years old, not pregnant or breastfeeding, and won't get pregnant during the study.
See 1 more
Treatment Details
Interventions
- Obicetrapib (CETP Inhibitor)
Trial OverviewThe study tests the effect of Obicetrapib (10 mg) on how quickly the body breaks down 'apo B100' in LDL cholesterol—often called bad cholesterol. The goal is to see if this drug can help improve lipid metabolism.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Obicetrapib 10 mgExperimental Treatment1 Intervention
10 mg tablets
Group II: Obicetrapib placeboPlacebo Group1 Intervention
identical matching placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
NewAmsterdam Pharma
Lead Sponsor
Trials
17
Recruited
13,900+
University of Pennsylvania
Collaborator
Trials
2,118
Recruited
45,270,000+
Dr. Joan Lau
University of Pennsylvania
Chief Executive Officer since 2020
PhD in Neuroscience from the University of Cincinnati College of Medicine, MBA from the Wharton School of Business, BS in Bioengineering from the University of Pennsylvania
Dr. Robert Iannone
University of Pennsylvania
Chief Medical Officer since 2019
MD from Yale University, MSCE from the University of Pennsylvania